doi: 10.1093/jac/44.4.533.
Dual inhibitory activity of sitafloxacin (DU-6859a) against DNA gyrase and topoisomerase IV of Streptococcus pneumoniae
Affiliations
- PMID: 10588315
- DOI: 10.1093/jac/44.4.533
Item in Clipboard
Dual inhibitory activity of sitafloxacin (DU-6859a) against DNA gyrase and topoisomerase IV of Streptococcus pneumoniae
J Antimicrob Chemother.
1999 Oct.
Abstract
The in-vitro inhibitory activities of sitafloxacin (DU-6859a) and other quinolones against Streptococcus pneumoniae DNA gyrase and topoisomerase IV were measured. IC50s of levofloxacin, ciprofloxacin, sparfloxacin and tosufloxacin against DNA gyrase were almost three to 12 times higher than those against topoisomerase IV. On the other hand, sitafloxacin showed dual inhibitory activity against both enzymes and its IC50s were the lowest among those of the quinolones tested. These results suggest that sitafloxacin is an effective agent against pneumococcal infections and that the incidence of drug-resistant mutants is low.
Similar articles
-
Purification of pneumococcal type II topoisomerases and inhibition by gemifloxacin and other quinolones.J Antimicrob Chemother. 2000 Apr;45 Suppl 1:101-6. doi: 10.1093/jac/45.suppl_3.101. J Antimicrob Chemother. 2000. PMID: 10824040
-
Activities of fluoroquinolones against Streptococcus pneumoniae type II topoisomerases purified as recombinant proteins.Antimicrob Agents Chemother. 1999 Nov;43(11):2579-85. doi: 10.1128/AAC.43.11.2579. Antimicrob Agents Chemother. 1999. PMID: 10543732 Free PMC article.
-
Cleavable-complex formation by wild-type and quinolone-resistant Streptococcus pneumoniae type II topoisomerases mediated by gemifloxacin and other fluoroquinolones.Antimicrob Agents Chemother. 2002 Feb;46(2):413-9. doi: 10.1128/AAC.46.2.413-419.2002. Antimicrob Agents Chemother. 2002. PMID: 11796351 Free PMC article.
-
Dual activity of fluoroquinolones against Streptococcus pneumoniae: the facts behind the claims.J Antimicrob Chemother. 2002 Jun;49(6):893-5. doi: 10.1093/jac/dkf047. J Antimicrob Chemother. 2002. PMID: 12039880 Review. No abstract available.
-
Mechanisms of action and resistance of older and newer fluoroquinolones.Clin Infect Dis. 2000 Aug;31 Suppl 2:S24-8. doi: 10.1086/314056. Clin Infect Dis. 2000. PMID: 10984324 Review.
Cited by
-
Recent Biochemical Advances in Antitubercular Drugs: Challenges and Future.Curr Top Med Chem. 2024;24(21):1829-1855. doi: 10.2174/0115680266286294240610102911. Curr Top Med Chem. 2024. PMID: 38919089 Review.
-
Quinolone Resistance: Older Concepts and Newer Developments.Curr Infect Dis Rep. 2001 Feb;3(1):20-28. doi: 10.1007/s11908-001-0055-y. Curr Infect Dis Rep. 2001. PMID: 11177727
-
Target preference of 15 quinolones against Staphylococcus aureus, based on antibacterial activities and target inhibition.Antimicrob Agents Chemother. 2001 Dec;45(12):3544-7. doi: 10.1128/AAC.45.12.3544-3547.2001. Antimicrob Agents Chemother. 2001. PMID: 11709337 Free PMC article.
-
Grepafloxacin, a dimethyl derivative of ciprofloxacin, acts preferentially through gyrase in Streptococcus pneumoniae: role of the C-5 group in target specificity.Antimicrob Agents Chemother. 2002 Feb;46(2):582-5. doi: 10.1128/AAC.46.2.582-585.2002. Antimicrob Agents Chemother. 2002. PMID: 11796384 Free PMC article.
-
Contributions of the 8-methoxy group of gatifloxacin to resistance selectivity, target preference, and antibacterial activity against Streptococcus pneumoniae.Antimicrob Agents Chemother. 2001 Jun;45(6):1649-53. doi: 10.1128/AAC.45.6.1649-1653.2001. Antimicrob Agents Chemother. 2001. PMID: 11353607 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
